| abstract |
PROBLEM TO BE SOLVED: To provide a selective ETA receptor antagonist and therapeutic combination for use in a method for increasing blood glucose control and / or insulin sensitivity in a human subject having diabetic nephropathy and / or metabolic syndrome. Atrasentan or a salt thereof is combined with an angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker for use in a method of treating diabetic nephropathy in a human subject having diabetic nephropathy. A drug, wherein the method comprises administering to a subject at least one dose of atrasentan or a salt thereof and an angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker. [Selection] Figure 1 |